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α-DioxygenaseProstaglandin H2 synthase (PGHS; EC 1.14.99.1), a bi-functional heme enzyme that contains cyclooxygenase and
peroxidase activities, plays a central role in the inﬂammatory response, pain, and blood clotting in higher eukary-
otes. In this review, we discuss the progenitors of the mammalian enzyme by using modern bioinformatics and
homology modeling to draw comparisons between this well-studied system and its orthologs from algae and
bacterial sources. A clade of bacterial and algal orthologs is described that have salient structural features distinct
from eukaryotic counterparts, including the lack of a dimerization and EGF-like domains, the absence of gene
duplicates, and minimal membrane-binding domains. The functional implications of shared and variant features
are discussed.
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Prostaglandin H2 synthase (PGHS; EC 1.14.99.1) is a monotopic
integral membrane protein that resides within the outer leaﬂet of the
endoplasmic reticulum. Inmammals, it catalyzes theﬁrst step in the for-
mation of prostanoids. This class of potent fatty acid autocoids regulates
a wide array of physiological processes, including the pathophysiology
of cardiovascular disease [1,2], inﬂammation [3–5], tumorigenesis
[6–10], andAlzheimer's disease [11]. PGHS acts as a bi-functional homo-
dimer; each monomer contributes distinct cyclooxygenase and peroxi-
dase active sites that employ a heme cofactor. Within the dimer, these
active sites work in concert via an allosteric “half-of-sites” mechanism
[12–16] to transform arachidonic acid into PGH2 by sequential oxidation
and reduction steps [17]. The study of this enzyme is very mature, well-
informed by decades of detailed biochemistry, x-ray crystallography,
and the extensive development of isoform-speciﬁc inhibitors for clinical
use (reviewed in [17–19] andmany other articles). This wealth of infor-
mation provides a valuable point of departure fromwhich detailed com-
parisons with primitive homologs can be made to gain evolutionary
insight into structure and function.
In contrast, relatively little is known about the orthologs of PGHS
from more primitive organisms, such as bacteria, algae, and fungi. As-
signment of these many orthologs to the peroxidase-cyclooxygenase
superfamily is based largely on sequence relationships [20]; only most
recently have select orthologs been characterized in vitro to directly as-
sess this relationship [21,22]. While the endoplasmic reticulum is com-
mon to all eukaryotic organisms, the presence of PGHS orthologs in
lower organisms invokes a number of intuitive questions regarding evo-
lution, structure, and function. Are all bacterial and algal orthologs of
PGHS also integral membrane proteins? Did mammalian PGHS origi-
nate from a soluble ancestor? What biological roles do their respective
lipid product proﬁles play in these more primitive organisms? Among
prokaryotes, the selection of unique chemical reactions that yield bioac-
tive metabolites is presumably driven in part by persistent immersion
within the lipid bilayer, providing access to a concentrated source of hy-
drophobic substrates. The lipid composition of various prokaryotes
varies signiﬁcantly from species-to-species, even within the same
genus [23]. Hence, selective metabolic pressure could drive diversity
among prokaryotic PGHS orthologs, both kinetically and structurally,
in a way not seen in higher organisms.
The presence of two spatially distinct active sites within the
mammalian PGHS open reading frame (ORF) product raises additional
questions about the evolutionary path by which these two active sites
were married. Given the abundance of peroxidases across genomes,
an ancient peroxidase probably incorporated a second active site and
a membrane-binding motif through evolution, whereas an alternative
hypothesis advocates the advent of a peroxidase active site within a
cyclooxygenase precursor [24]. The oligomeric properties of mammali-
an PGHS underlie its concerted “half-of-sites” mechanism of catalysis
and the interplay between both active sites. However, the oligomeric
and kinetic properties of the primitive orthologs identiﬁed are not as
well understood. If themore primitive orthologs of PGHS have different
oligomeric properties, howdoes themechanism of catalysis change, if at
all? In the only algal ortholog characterized in vitro, the recombinant
protein ably converts arachidonic acid to PGG2 and PGH2, but behaves
as a tetramer by size-exclusion chromatography [22]. In the only bacte-
rial ortholog characterized to date, the cyanobacterial ‘cyclooxygenase’
(actually characterized as a dioxygenase) identiﬁed from Nostocpunctiforme is proposed to work in tandem with a neighboring up-
stream fatty acid heme hydroperoxide lyase gene rather than provide
two distinct activities, and shows strong preference for oleic and linoleic
acid over arachidonic acid [21]. While the recombinant algal protein re-
quired detergent for solubility, the bacterial protein did not. These initial
observations together indicate that these orthologs are diverse and
functionally distinct from their eukaryotic counterparts.
In this review,we consider these functional implications froma struc-
tural point-of-view, comparing thewell-characterized eukaryotic protein
with its homologs within the peroxidase-cyclooxygenase superfamily
from more primitive species. The structural study of eukaryotic PGHS in
itself is a very well-developed area of study, with greater than ﬁfty crys-
tallographic structures available in the Protein Data Bank (PDB); the
properties of its structural domains are well-deﬁned and have been
recently reviewed [25]. These structural domains guide discussion of
more primitive orthologs, with a particular emphasis on a clade of bacte-
rial enzymes already identiﬁed by bioinformatics for which no represen-
tative experimental crystal structures are currently available. These
orthologs present an exciting opportunity to further our knowledge of
many aspects of PGHS structure and function, including structure-
function relationships, tyrosyl radical formation and substrate reactivity,
substrate and inhibitor selectivity, kinetics, and structural allostery.
2. Canonical properties of mammalian prostaglandin H2 synthases
Inmammals, there are two primary isoformswhich differ not only in
their expression patterns and gene regulation but also in the organiza-
tion of the cyclooxygenase site. Both mammalian PGHS-1 and PGHS-2
are highly conserved, with 85-90% identity within both isoforms [26].
The ﬁrst isoform, PGHS-1, is generally described as a constitutively-
expressed isoform involved in “housekeeping” functions, while PGHS-
2 expression is induced in response to inﬂammatory stimuli. Both iso-
forms of this enzyme are the site of action of nonsteroidal anti-
inﬂammatory drugs (NSAIDs, e.g. aspirin, ibuprofen, indomethacin),
clinically important molecules that, via the inhibition of the cyclooxy-
genase active site of PGHS, target the regulation of pain, the inﬂamma-
tory response, and blood clotting (reviewed in [18]). In the same
organism, the primary sequences of PGHS-1 and PGHS-2 are approxi-
mately 60-65% homologous. Despite this high sequence similarity, a
number of smallmolecules have been successfully engineered that pref-
erentially block the cyclooxygenase active site of one isoform over the
other [27–29].
The three-dimensional structure of ovine PGHS-1 was ﬁrst reported
in 1994 at 3.5 Å resolution [24], among the ﬁrst integral membrane pro-
tein structures to be determined by x-ray crystallography (Fig. 1A).
Crystal structures of human andmouse PGHS-2 at low andmedium res-
olution followed in 1996 [30,31]. X-ray crystallographic studies have
demonstrated that the structures of the eukaryotic PGHS isoforms are
nearly superimposable, providing a complete structural view of the do-
mains of PGHS, within the context of a crystallographic dimer.
All mammalian PGHSs display high similarity in sequence and do-
main structure (Fig. 1B). An N-terminal signal peptide precedes an epi-
dermal growth factor-like (EGF) domain. This domain is followed by a
membrane-binding domain, a short dimerization domain [32,33], a
globular catalytic peroxidase domain distinguished by a peroxidase
fold similar to that found in cytochrome c peroxidase [34] and other
classical peroxidases, and a C-terminal segment that is implicated in re-
tention of the protein by the endoplasmic reticulum [25]. We will now
Fig. 1. A. Crystal structure of ovine PGHS-1 (PDB ID: 1Q4G). The structural domains are colored as such: the EGF-like domain, green; the membrane-binding domain, yellow; the second
dimerization domain, orange; the catalytic domain, blue. The structural elements (in black) attached to the soluble region of the structure represent glycosylation sites; the unattached
structures near the membrane binding domain are molecules of the detergent β-octylglucoside identiﬁed during structural reﬁnement. This ﬁgure was prepared using PYMOL [105]. B.
Schematic diagram of ovine PGHS-1 sequence with structural features denoted. The protein features an N-terminal EGF-like domain (EGF, green), followed by a membrane-binding
domain (MBD, yellow), a second dimerization domain (2DD, orange) and a catalytic domain (blue). PTEL refers to the ﬁnal four residues in the protein sequence associated with an ER
retention signal [106].
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as the point of reference for discussion of sequence boundaries and
structure.
2.1. The EGF-like domain
The EGF-like domain (residues 31–69) contains seven conserved
cysteines that are known to participate in three intramolecular disulﬁde
linkages, along with a fourth disulﬁde bridging the EGF domain to the
catalytic domain. The domain is highly conserved across all eukaryotic
homologs of PGHS, with N42% identity across all available eukaryotic
PGHS sequences and N63% identity between isoforms within a species.
A DALI database [35] search of the domain against the holdings of the
Protein Data Bank reveals over sixty structures with N30% sequence
identity and structural homology, which is not surprising given the
ubiquitous distribution of this modular domain across eukaryotic ge-
nomes (N1100 cataloged in UniProt). EGF-like domains have only
been detected in eukaryotic genomes [36] and in the animal viruses
[37]. Glycosylation of EGF-like modules is common in eukaryotes. In
PGHS, modiﬁed sites at Asn68, Asn144, and Asn410 in PGHS-1 [38,39]
and Asn53, Asn130, Asn396, and Asn580 in PGHS-2 have been con-
ﬁrmed [40].
2.2. The membrane-binding domain (MBD)
All of the mammalian PGHS proteins include a membrane binding
domain comprised of four amphipathic α-helices (amino acids 69–
116 in ovine PGHS-1, denoted helices A–D) that anchor the enzyme to
the endoplasmic reticulum. In additional to solubilizing detergents ob-
served within the crystallographic lattice [41], a wealth of biochemical
analyses, including detergent binding studies [42], site-directed muta-
genesis [43], and molecular modeling [44] strongly support a structural
model in which the four amphipathic helices lie adjacent to the mem-
brane acyl chains at speciﬁc sites and anchor PGHS to the outer leaﬂet
of the membrane bilayer, parallel to its plane. Hydrophobic residues in
the helices are predicted to interact with fatty acyl chains in the mem-
brane, while hydrophilic groups are exposed to the membrane surface
and interact with polar phospholipid head groups, and with water.
These modeling studies additionally predicted that the fatty acid sub-
strate enclosed within the center of a motif formed by the four helices
form an electrostatic interaction with Arg120 in the PGHS active site
[44], a critical interaction for both drug-binding and catalysis, which
was conﬁrmed by x-ray crystallography.Of the domains present in PGHS, the membrane binding helices dis-
plays the greatest sequence variability between mammalian species,
with ~38% sequence homology versus greater than 70% homology for
the rest of the protein [43,45]. Sequence variations are predicted tomod-
ify the binding energy between the amphipathic helices and amembrane
bilayer. Calculations have predicted that each subunit of the ovine PGHS-
1 dimer is anchored into the endoplasmic reticulumwith approximately
37 kcal/mol of energy per subunit, while in murine PGHS-2 this interac-
tion energy is much lower (approximately 7 kcal/mol) [33]. In agree-
ment, binding experiments demonstrate that ovine PGHS-1 is stably
attached to the membrane surface, with signiﬁcant expansion in the
membrane surface to allow for its insertion, while murine PGHS-2
shows less signiﬁcant perturbation of the lipid bilayer [46].
2.3. The second oligomerization domain of PGHS and dimerization
Residues 116–140 in PGHS, along with the EGF-like domain, com-
prise the dimeric interface observed by X-ray crystallography. This in-
terface buries 2893 Å2, corresponding to 13% of the total solvent
accessible surface [41]. In eukaryotic proteins, the dimeric structure of
PGHS has been shown to be required for enzymatic function. Reversible
disruption of the PGHSdimer bymild denaturation yields amonomeric-
but-folded enzyme that lacks cyclooxygenase activity; activity is
regained following removal of denaturant [47]. More recent studies
with mammalian PGHS homodimers indicate that occupation of the ac-
tive site of one monomer in the dimer prevents binding of substrate or
inhibitor to the second monomer [12–16].
2.4. The catalytic domain
PGHSbelongs to a superfamily that includes both peroxidase and cy-
clooxygenase enzymes. The catalytic domain of PGHS comprises the
bulk of the monomer chain and contains both the cyclooxygenase and
peroxidase active sites. These active sites are spatially distinct, located
on opposite sides of the catalytic domain, with no evidence for any
direct internal connections between the two sites [13,19,48,49].
Peroxidases are ubiquitous and found in all organisms, but a subset
of theses peroxidases have developed a second enzymatic activity.
Mammalian PGHS displays similarity in sequence and overall
fold with thyroid peroxidase and the catalytic domain of canine
myeloperoxidase [24,41,50,51]. In the latter case, this structural homol-
ogy extends across the ovine PGHS catalytic domain, with the main he-
lices involved in heme binding superimposing with a ~1.4 Å RMSD.
Plant peroxidases which also display these similarities in fold include
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cant structural differences between PGHS and myeloperoxidase are the
lack of a membrane binding domain in myeloperoxidase, variations in
the dimerization domains, lack of a cyclooxygenase active site, and
modiﬁcations in the catalytic region that allow greater solvent accessi-
bility to the heme. Like PGHS, myeloperoxidase is glycosylated.
2.4.1. The cyclooxygenase active site
A large number of crystallographic structures of both isoforms of eu-
karyotic PGHS inform our understanding of fatty acid substrate binding
and catalysis [52–56] (Fig. 2). To successfully capture the substrate in its
Michaelis complex within the cyclooxygenase active sites, alternative
heme cofactors (e.g., Co(III) protoporphyrin IX) or apo enzyme was uti-
lized to remove any trace amounts of catalytic activity (Fig. 2).
Site-directedmutagenesis and x-ray crystallography have revealed a
number of salient features of the cyclooxygenase active site within the
eukaryotic enzyme. The active site resides at the apex of a long, narrow,
hydrophobic channel (~8 × 25 Å), which leads from the membrane-
binding domain deep into the catalytic domain [24]. The channel nar-
rows at the meeting of the side-chains from residues Arg120, Tyr355,
and Glu524; this triad comprises a constriction throughwhich substrate
must pass to enter the active site. It is clear from crystallographic anal-
ysis that some rearrangement of this constriction must occur to allow
for the passage of substrate into and out of the active site. Two residues
(Arg120 and Tyr355) have been shown to interact with the substrateFig. 2.The prokaryotic homologs of PGHSwere threadedonto the ovine PGHS-1 template structu
relaxed by energy minimization in a solvated environment using the programs VMD [108] and
was evaluated using the MOLPROBITY server [110]. N90% of the residues resided in the allowab
Themodelwas rendered using the programPYMOL [105]. A. A comparison of the cyclooxygenas
(1Q4G, [41]) forms, alongside the homologymodels for algal (Gracilaria) and bacterial (Nostoc)
those predicted by homology modeling for algal (Gracilaria) and bacterial (Nostoc) homologs.carboxylate group [24,57] as well as similar chemical moieties in
NSAIDs. The presence of Arg120 is critical for substrate binding to
PGHS-1; an Arg120Glu mutation increases the KM for arachidonic acid
by ~100 fold and Arg120Gln by ~825 fold [58,59]. By crystallography,
arachidonic acid is found oriented in an extended “L-shape” conforma-
tion within the active. Ser530, the residue covalently modiﬁed by the
inhibitor aspirin [60,61], is buttressed against carbons 12-14 of the sub-
strate [52] (see Fig. 2); similar conﬁgurations are observed in PGHS-2
[56] andwith alternative fatty acid substrates [54,55]. Carbon 13 of ara-
chidonic acid is positioned 2.8 Å away from the phenolic oxygen of
Tyr385, which is converted to the radical species which initiates the cy-
clooxygenase activity by extraction of the proS hydrogen of carbon 13.
Carbons 14–20 (theω-end) of this substrate is nestedwithin in a hydro-
phobic cleft adjacent to Ser530. The vast majority of the interactions
that the substrate makes with the enzyme are hydrophobic in nature
[52].
The active site in eukaryotic PGHS is promiscuous in nature,
encompassing a wide variety of alternative fatty acid substrates
and small molecules. Substrates that include linoleic acid, di-homo-
γ-linoleic acid, and eicosapentaenoic acid have been shown to bind
in very similar orientations, corresponding to different trends in cat-
alytic efﬁciency [54,55]. These catalytic differences are presumably
due to misalignment of the substrate relative to Tyr385, which un-
dermines the precise active site arrangement required for proS hy-
drogen extraction. Furthermore, the ﬁdelity of the reaction is notre (PDB ID: 1Q4G) using the PHYRE v2.0 server [107]. The resultingmodelswere gradually
NAMD [109], using CHARMM42 force ﬁelds. The overall quality of this minimized model
le regions of a Ramachandran plot and showed generally good stereochemical properties.
e active sites of PGHS fromOvis aries in the arachidonic acid (1DIY, [52]) andNSAID-bound
PGHS in NSAID-bound states. B. A comparison of the ovine PGHS-1 peroxidase active with
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donic acid is prostaglandin G2, the minor products 11R-hydroxy-
5Z,8Z,12E,14Z-eicosatetraenoic acid (11R-HETE), 15S-hydroxy-
5Z,8Z,11Z,13E-eicosatetraenoic acid (15S-HETE), and 15R-HETE are
also produced [62,63]. The relative amounts of these minor products
differ between isoforms and species, and can be readily modiﬁed by
site-directed mutagenesis.
2.4.2. The peroxidase active site
The peroxidase cycle of ovine PGHS is as robust as other well-
characterized heme peroxidases [33,64], but is distinguished by the res-
idues that comprise the heme binding site. The peroxidase activity of
eukaryotic PGHS is primarily dependent upon the presence of Gln203
and His207 at the heme's distal face and His388, the proximal heme li-
gand (Fig. 2). Mutations of these residues lead to a marked reduction or
elimination of peroxidase activity [65,66]. By x-ray crystallography,
His388 is seen to participate in a hydrogen bonded network with
Tyr504 and His386 via a well-ordered bridging water molecule [41]. In
contrast, in related peroxidases such as horseradish peroxidase, the
proximal histidine instead forms a strong salt bridge with an adjacent
aspartate [67]; in myeloperoxidase, the adjacent residue is an aspara-
gine [68].
The distal face of the heme cofactor in ovine PGHS-1 is largely de-
ﬁned by two residues: the distal heme ligand His207 and Gln203
(Fig. 2). In ovine PGHS-1, His207 is closest to the heme and is believed
to assist in the deprotonation of the peroxidase substrate. His207 is con-
served throughout all eukaryotic PGHS examples, and also in the related
α-dioxygenase (vida infra). Heme iron ligands such as carbonmonoxide
or cyanide bind to the distal side of the iron [69], and glycerol has also
been seen to bind to this site [41]. The adjacent glutamine residue
(Gln203) also appears to participate in peroxidase substrate binding.
PGHS is believed to utilize a “push-and-pull” mechanism for catalysis
[70]. In ovine PGHS, Gln203 and His207 have been proposed to work
in tandem in this regard to provide the “pull” for this mechanism.
3. The progenitors of mammalian prostaglandin H2 synthases
3.1. Prostaglandin H2 synthase homologs from crustaceans, coral, and alga
PeroxiBase [71] curates a collection of peroxidase-related genes
from all kingdoms of life, including 95 entries for open-reading frames
(ORFs) which are predicted to possess structural homology to ovine
PGHS based on primary sequence. In addition to mammalian ORFs, ad-
ditional PGHS genes have been reported from a number of additional
more primitive vertebrate [72] invertebrate, and plant species, includ-
ing crustacean, coral, and algae [22,68,73–75]. Table 1 provides a synop-
sis of the level of similarity observed between orthologs of PGHS-1,
using ovine PGHS-1 as a point of reference. Coral PGHS sequences areTable 1
Sequence comparisons between PGHS and related genes from various organisms compared to o
where the same amino acid is conserved, while positives represent identities or residues with
Identities
Eukaryotes
Homo sapiens (human) 534/576 (93%
Mus musculus (mouse) 504/576 (88%
Xenopus laevis (frog) 412/552 (75%
Danio rerio (zebraﬁsh) 364/556 (65%
Plexaura homomalla (coral) 280/555 (50%
Gammarus sp. (crustacean) 253/555 (46%
Gersemia fruticosa (coral) 277/555 (50%
Gracilaria vermiculophylla (red algae) 132/529 (25%
Prokaryotes
Nostoc punctiforme (cyanobacterium) 149/523 (28%
Rhodobacter sphaeroides (alphaproteobacterium) 141/497 (28%
Nitrosospira_multiformis (betaproteobacterium) 186/492 (34%50%homologous to ovine PGHS-1, and recombinant coral PGHS exhibits
both cyclooxygenase and peroxidase enzyme activity [73,74]. Similarly,
the single characterized algal PGHS sequence is 25% identical to ovine
PGHS-1 and in vitro also displays cyclooxygenase and peroxidase activ-
ities. Neither coral nor algal enzymes demonstrate signiﬁcant inhibition
by NSAIDs [22,74,76,77].
Among eukaryotic PGHS proteins, crystallographic structures are
available only frommammalian examples. Hence, evolutionary insights
into structure and function can only be inferred from sequence analysis
and enzymology. All eukaryotic orthologs contain sequences consistent
with the domains common to mammalian PGHS, and all require deter-
gent to isolate in an active form. Of the known orthologs, all prefer
arachidonic acid as substrate, and all but the enzyme from the coral
Plexaura homomalla generate PGG2 as their major cyclooxygenase
product. Subspecies of P. homomalla have been identiﬁed that encode
for orthologs that prefer either the corresponding 15R or 15S-
hydroperoxide [77,78]. A single point mutation (Val349Ile) effectively
was found tomodulate this stereochemical preference. This observation
is somewhat reminiscent of the inability of aspirin-acetylated mamma-
lian PGHS-1 (at residue 530) to produce the minor product 15R-HETE
[79] and the associated role of Val349 in the control of stereochemistry
at theposition 15 of substrate [80]. Together, these results illustrate how
subtle changes within the cyclooxygenase active site can affect the
dioxygen attack of the lipid substrate and the resulting lipid proﬁle.
3.2. The peroxidase fold is the unifying feature of all prostaglandin H2
synthase homologs
Phylogenetic analyses of these entries using both the Phylogeny.fr re-
source [81] and prototype animal heme peroxidases as a reference
group provide insight into the evolutionary relationships among the
structural homologs of mammalian PGHS. Fig. 3 provides a cladogram
summarizing the relationships between four distinct clusters in our
analysis: (I) prototype animal heme peroxidases, (II) PGHS orthologs
from gamma- and delta-proteobacteria, sac fungi, and plants, (III)
orthologs from alpha- and betaproteobacteria and algae, and (IV)
eukaryotic PGHSs. The full phylogenetic analysis is provided in Supple-
mental Fig. 1. Where available, structural prototypes for which crystal
structures are available are also shown, revealing both conserved and
absent features between the clades. We will next discuss the basic
features of these prototype peroxidases before drawing contrast with
evolutionarily related PGHS enzymes from lower organisms.
3.2.1. Phylogeny of peroxidases
A phylogenetic relationship between the different mammalian per-
oxidases previously has been proposed [20]. The peroxidase domains
of 134 heme-containing enzymes were analyzed using the maximum
likelihood method, and divided into seven distinct subfamilies:vine PGHS-1. Sequence alignmentswere performed in BLAST [104]. Identities indicate sites
similar size or charge properties. Ovine PGHS-1 contains 600 amino acids.
Positives Gaps
) 554/576 (96%) 0/576
) 537/576 (93%) 0/576
) 479/552 (86%) 0/552
) 451/556 (81%) 2/556 (b1%)
) 378/555 (68%) 7/555 (1%)
) 373/555 (67%) 8/555 (1%)
) 375/555 (67%) 7/555 (1%)
) 240/529 (45%) 83/529 (15%)
) 241/523 (46%) 55/523 (10%)
) 221/497 (44%) 57/497 (11%)
) 251/492 (51%) 54/492 (10%)
Fig. 3. Evolutionary relationship of PGHS homologs. A. Shown is an unrooted phylogenetic tree that summarizes the sequence relationship between PGHS homology cataloged in
PeroxiBase. ORF sequences from 96 cataloged sequences were aligned and a maximum-likelihood tree calculated using PhyML [111]. Alignments were prepared with ClustalW [112]
and trees were visualized using TREEDYN [113]. These software packages are available at http://www.phylogeny.fr/ [81]. A detailed phylogenetic tree resulting from this analysis is pro-
vided as Supplemental Fig. 1. B. Shown are three available crystal structures representing different evolutionary clades in this group of homologs: Canine lupus familiarismyeloperoxidase
(1MYP, a prototype animal hemeperoxidase),Oryza sativaα-dioxygenase (4KVK, anα-dioxygenase-like ortholog), andOvis ariesprostaglandingH2 synthase (1Q4G, theprototype animal
PGHS). No experimental structure of a representative from the bacterial and algal PGHS clade (III) is currently available.
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peroxidockerins, and dual oxidases. In that analysis, the prostaglandin
synthases, also referred to as cyclooxygenases, were further subdivided
into two clades: the mammalian PGHS proteins and their bacterial ho-
mologs represent one clade, while the plant and fungal PGHS proteins
comprise the second clade [20]. These results are similar in nature to
the relationships forwarded by our phylogenetic analysis (Fig. 3). The
unifying feature of the peroxidase superfamily is the classic peroxidase
fold with bound heme cofactor. However, most peroxidases lack fea-
tures that distinguish eukaryotic PGHS, including a dimeric interface, a
second distinct active site, and a membrane-binding domain. Within
the prostaglandin synthases, sequence similarity has been identiﬁed
with a number of gene products from a diverse number of species,
including linoleate diol synthase, rice α-oxygenase, and the aforemen-
tioned cyclooxygenases identiﬁed in sea coral [77,82,83].
3.3. Group II: fungal and plant orthologs of PGHS
Putative and known fungal sequences within this clade of PGHS
orthologs are remarkably similar to one another (greater than 42% se-
quence identity and 53% positive correlation in the most disparate
cases), highly suggestive of a common origin, structure, and function.
Many of the organisms within this clade prosper in fecund environ-
ments and may exist in close contact (e.g. mold and bacteria in the
soil, alongside plants), raising the distinct possibility of lateral DNA
transfer.
Fungal ORFs display the least sequence homology to their mamma-
lian counterparts. Notably, this clade does bear a close sequence
relationship to α-dioxygenase (α-DOX) from rice, suggesting that the
members of this clade are evolutionary precursors closer to α-DOX in
structure and function than eukaryotic PGHS.
3.3.1. α-Dioxygenase
α-Dioxygenases (α-DOX) catalyze the oxidation of fatty acids into
2-hydroperoxides. The reaction proceeds via a radicalmechanismby re-
moval of the pro-R hydrogen from C2 of a fatty acid substrate, followed
by addition of molecular oxygen to generate the hydroperoxide. Theunstable product can spontaneously lose a carboxylate moiety to form
the corresponding aldehyde, or can be reduced by peroxidases to form
a 2-hydroxy fatty acid [84]. The structure of α-DOX isolated from
Arabidopsis thaliana was recently determined to 1.5 Å resolution [85],
providing a unique high-resolution insight into the evolution of PGHS.
At the N-terminus of α-DOX is a series of eight amphipathic helices,
reminiscent of the PGHS membrane binding domain. From its crystal
structure, α-DOX is apparently monomeric [85], while mammalian
PGHS proteins are dimeric both in solution and the crystal lattice.
With regards to the ﬁrst active site,α-DOX displays similar architec-
tural features to PGHS, with a catalytic tyrosine (Tyr386) required for
hydrogen atom abstraction from the fatty acid substrate. However, the
architecture of the fatty acid binding site is different in α-DOX relative
to PGHS, resulting in hydrogen abstraction and oxygen addition at C2
of the fatty acid. The structure observed at the two faces of the bound
heme of α-DOX is also similar to PGHS, with His389 (analogous to
His388 of PGHS) at the proximal side of the porphyrin ring and His163
and Gln159 (analogous to His207 and Gln203 in PGHS) on the distal
face. The mutation Gln159Arg in α-dioxygenase completely abolishes
oxygenase activity [86], but mutation of the same residue to Asn, Ser,
or Val generates enzymes with greater than 75% of native activity [85].
In contrast to PGHS,α-DOX exhibits virtually no peroxidase activity,
which is attributed to two peptide loops that limit the access of perox-
idase substrates to the distal face of the heme [85]. This result, along
with sequence alignments of othermembers of this clademight suggest
that not all of the orthologs of this group may have retained bona ﬁde
peroxidase activity. For example, a sequence analysis of a putative
PGHS identiﬁed in theNeurospora crassa genome indicateswhile the cy-
clooxygenase site appears largely intact, signature sequences associated
with hemebinding (including the proximal and distal histidine ligands)
are not evident. This suggests that the peroxidase activity in this PGHS
ortholog might be altered and the heme binding site remains only as a
vestigial element.
3.3.2. Linoleate diol synthase
Linoleate diol synthases (LDS) are prevalent in fungi, and catalyze
the addition of molecular oxygen to several sites in unsaturated C18
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LDS and PGHS. Their recent work has concentrated upon two experi-
mental systems: 7,8-LDS from Gaeumannomyces graminis, and the 5,8-
LDS from Aspergillus fumigatus. In the G. graminis LDS, the authors per-
formed a sequence alignment with ovine PGHS-1, identifying regions
of functional overlap [82]. Later, amino acids in G. graminis LDS were
mutagenized that correspond to residues known to be critical for
PGHS cyclooxygenase activity. Several mutations exhibited reduced
dioxygenase activity, as predicted from comparison with PGHS
mutations, while others did not behave as expected [88]. Later, similar
sequence homology was observed between ovine PGHS-1 and the 5,8-
LDS of Aspergillus fumigatus [89]. Based upon sequence alignments, a
truncated version of 5,8-LDS was prepared; the shorter construct
retained 8-LDS dioxygenase activity. Mutagenesis of a critical tyrosine
residue necessary for hydrogen atom abstraction completely abolished
enzyme activity, as predicted from comparison with PGHS-1 [90].
While there is some limited sequence homology between LDS and
PGHS-1, there is no structural data available for this class of enzymes.
Structure prediction does not generate the structural elements typically
associated with PGHS.
3.4. Group III: bacterial and algal orthologs of PGHS
The PeroxiBase collection contains eleven structural homologs to
PGHS that are bacterial in origin. Unfortunately, there are no available
high-resolution structures of members within this group that directly
reveal their structural properties. As aforementioned, the enzyme
from Nostoc punctiforme was recently expressed and characterized as
a 10S-dioxygenase [21]. The dioxygenase is proposed towork in tandem
with an upstream ORF for a catalase that converts the 10S hydroperox-
ide product of the dioxygenase enzyme to the corresponding alcohol.
Notably, the recombinantNostoc enzyme can be expressed and isolated
as a soluble enzyme, in contrast to eukaryotic counterparts that require
detergent for solubilization [21].
The degree of amino acid sequence homology between bacterial and
eukaryotic PGHS orthologs is shown in Table 1, and a more detailed se-
quence alignment of two bacterial and one algal PGHS ORFs is provided
in Fig. 4. In general, the bacterial orthologs display approximately
~20–30% sequence homologies relative to ovine PGHS and one another.
For example, a pairwise comparison of theNostoc 10S-dioxygenasewith
sequences for putative PGHS proteins from Gracilaria and Rhodobacter
yield overall identities of 27% and 36%, respectively. The observed
activity in the Nostoc enzyme suggests that the other identiﬁed ORFs
also encode for dioxygenases, but the poor sequence homology
decreases conﬁdence in this assumption.
This group of bacterial orthologs can be further segregated
by size. Two of the ORFs (from Streptomyces avermitilis and
Oceanobacter_sp.) have greater than ~900 amino acids; these align
poorly with the other 11 examples and for that reason have been
eliminated from this analysis. The remaining ORFs display reasonable
sequence homology and are further distinguished by length: one
group (“medium”) has four members (Mycobacterium smegmatis;
Acaryochloris marina; Microcoleus chthonoplastes; Solibacter usitatus)
with between 583 to 618 amino acids, while the other group
(“small”) has seven members (Mycobacterium vanbaalenii; Nostoc
punctiforme; Roseobacter denitriﬁcans; Rhodobacter sphaeroides;
Nitrosomonas europaea; Nitrosospira multiformis (2 entries)) with be-
tween 528 and 550 amino acids. All of the bacterial genes are weakly
homologous with mammalian PGHS genes due to the lack of the EGF-
like domain and most of the dimerization domain found in eukaryotes.
The bacterial genes do contain amino acids weakly analogous to the
membrane binding domain, but with signiﬁcant alteration in sequence
and length.
The aforementioned discovery of a cyclooxygenase within the ge-
nome of the red algae Gracilaria vermiculophylla [22] was the ﬁrst such
non-animal cyclooxygenase to be identiﬁed and the only characterizedfrom this class of organisms. The observed homology between the algal
andmammalian enzymes is low relative to other pairwise comparisons
(Table 1).While the coral PGHS shows ~50%homology to ovine PGHS-1,
the algal PGHS only displays 25% homology. The algal protein shows
limited sequence homology to the bacterial ORFs, with 20-30% se-
quence homology. The most striking feature of these comparisons is
the size of the gaps in the alignment, ranging from ~1% in the coral en-
zyme to ~13% in the algal enzyme when compared to ovine PGHS.
The algal PGHS is a membrane-associated protein that requires
detergent extraction to complete its puriﬁcation and detergent in solu-
tion to maintain solubility. Accordingly, the authors present homology
modeling demonstrating the concordance between the algal sequence
and the ovine PGHS structure, except that the EGF-like domain and
one of themembrane-binding helices aremissing from the algal protein
[22]. In further support of their structural model, recombinant prepara-
tions of this algal homolog were shown to possess both cyclooxygenase
and peroxidase activities, utilizing a variety of C20 unsaturated fatty
acids as substrates.
4. Predicted relationship between sequence and structure in the
Group III PGHS orthologs
The recent characterization of PGHS structural homologs from algae
and cyanobacteria, with different substrate speciﬁcities and solubility
properties, provides a unique opportunity to speculate on the subtle
structural modiﬁcations that underlie their functional differences. We
next present a sequence and structural comparison of the well-known
structures of ovine PGHS with the sequence and predicted structures
of algal and bacterial homologs. The numbering convention correspond-
ing to ovine PGHS-1 provides the basis for comparison by amino acid. To
visually facilitate this comparison, we employed standard homology
modeling methods to create models of the active sites and heme bind-
ing regions of the PGHS orthologs from Gracilaria (algae) PGHS and
Nostoc (cyanobacteria) 10S-dioxygenase, using ovine PGHS-1 as the
template for threading (see Fig. 2 legend). All-atom superpositions of
these homology models with available eukaryotic experimental x-ray
structures are provided in Fig. 2 to underscore the predicted differences
in overall structure versus the mammalian prototype. These models
guide our subsequent discussion of these predicted differences.
4.1. Absence of an EGF-like domain region
A careful comparison and sequence alignment of the EGF-like region
in PGHS-1 and -2 from ﬁvemammalian species, trout, and zebraﬁshwas
previously reported [33]. If these sequences are aligned additionally
with the sequences for the coral cyclooxygenases (Plexaura and
Gersemia), strong sequence homology remains evident. Conserved
cysteines are also found in the coral and crustacean PGHS enzyme se-
quences, indicating that the disulﬁde bonds identiﬁed in the mammali-
an proteins are conserved and suggest that the three dimensional
structure of the EGF-like domain is largely retained through all verte-
brate and invertebrate PGHS enzymes.
In contrast, when the sequences from the algal and bacterial genes
are compared to ovine PGHS-1, no sequence correspondence to the
EGF-like domain is apparent. Also, unlike their eukaryotic counterparts,
the ORFs of the bacterial PGHS homologs do not include signal peptide
sequences [91], suggesting that the bacterial PGHS does not undergo
such targeting. In ovine PGHS-1, the EGF-like region ends near amino
acid 64. When the primary sequence of the Nostoc 10S-dioxygenase
ORF is aligned with ovine PGHS-1, we ﬁnd that the ﬁrst residue of the
Nostoc protein coincides with amino acid 59 of ovine PGHS-2, but
with very limited sequence homology in the N-terminal region.
Alignment of the algal PGHS with ovine PGHS-1 begins with amino
acid 56. Hence, the bacterial and algal orthologs lack the EGF andﬁrst di-
merization domains common to the mammalian PGHS prototypes.
Fig. 4. An alignment of the PGHS open reading frames from Rhodobacter sphaeroides; Nostoc punctiforme; and Gracilaria vermiculophylla relative to ovine PGHS-1. Alignments were
performed using ClustalX [112] and the ﬁgure generated using ESPript [114].
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this structural feature.
4.2. Is there a membrane binding domain in bacterial and algal orthologs?
As noted in Section 2.2, the membrane binding helices of PGHS dis-
play extensive sequence variability between mammalian species, with
~38% sequence homology versus greater than 70% homology for the
rest of the protein [43,45]. Amphipathic helices are predicted to occur
within the same regions of eukaryotic orthologs from both vertebrates
and invertebrates. Hydrophobic residues are found within this region
in all of the mammalian and ﬁsh PGHS proteins in their expected posi-
tions within the predicted helices, as well as within the coral orthologs.
These analyses strongly suggest that all eukaryotic PGHS examples exist
as monotopic membrane proteins.
In contrast, Group III bacterial and algal PGHS proteins display only
modest homology across regions corresponding with the membrane
binding domains of its eukaryotic counterparts. Fig. 4 compares the se-
quence of the membrane binding domain in ovine PGHS-1 with the
aligned amino acids from Nostoc, Rhodobacter, and the algal species
Gracilaria. While limited in sequence homology versus eukaryotic coun-
terparts, the aligned sequences in bacteria and algae are still predicted
to form α-helical structures. Secondary structure algorithms predict
multiple amphipathic helices in the N-terminal region of algal PGHS,
and homology modeling generates helices that correspond to the MBD
of ovine PGHS-1. The requirement of sodiumdeoxycholate to extract re-
combinant algal PGHS from the membranes of bacterial cells supports
this prediction [22]. In the absence of an experimental structure, avail-
able evidence strongly suggests that the algal PGHS contains a MBD in
its N-terminus similar to its mammalian counterpart.
In contrast, the recombinant preparations of Nostoc 10S-
dioxygenase are soluble in the absence of detergents [21]. Residues 15
to 60 of the Nostoc 10S-dioxygenase strongly correlate with the ﬁrst
four helices of the membrane binding domain of ovine PGHS-1. While
different in composition, the ﬁrst three predicted Nostoc helices, analo-
gous to amphipathic helices A-C in ovine PGHS-1, appear to be amphi-
pathic helices by secondary structure prediction. The structural
prediction program PredictProtein [92] also predicts partial membrane
burial of many of the residues in the helices, with less than 25% solvent
accessibility, consistent with the helices interacting on the membrane
surface. Inmammalian PGHS proteins, a fourth amphipathic helix is ori-
ented towards the active site relative to the plane of themembranewith
only the distal half of the helix interacting with the membrane, and is
believed to be less important in membrane binding than the ﬁrst
three helices [34]. Similarly, bioinformatics analysis of the Rhodobacter
ortholog also predicts four amphipathic helices in this region with sim-
ilar solvent accessibility.
Overall, these proteins contain structural elements that tentatively
assigned as membranes binding domains and more broadly, three
groups of structurally related proteins (plant α-dioxygenase, bacterial
linoleate dioxygenase, and algal PGHS) have been highlighted which
contain similar N-terminal amphipathic helices. However, the apparent
soluble property of theNostoc enzyme suggests thatmembrane binding
is not obligatory in this case. As noted previously, it is expected that both
composition in lipid and the protein component is expected to have
measureable impact on the protein association with membrane bilayer.
By virtue of comparison with membrane-bound relatives, this model
systemmay provide a unique opportunity to discern theminimal struc-
tural requirements for the transition from a soluble to
4.3. Bacterial and algal orthologs are predicted to be monomeric
Limited sequence homology is predicted between the bacterial and
mammalian proteins in part of the second dimerization domain
(amino acids 156-177 in ovine PGHS-1), whereas in contrast, ovine
PGHS-1 and PGHS-2 showvery strong identity in this region. This regionis largely devoid of secondary structure in available eukaryotic struc-
tures, and is partially absent among this group of bacterial and algal
homologs.
When the bacterial and algal sequences in this region are examined
by sequence alignment (Fig. 4), little resemblance to either eukaryotic
isoform is apparent between amino acids 157-170, including sizeable
gaps. The absence of a second dimerization domain, coupled with the
lack of an EGF-like domain believed to contribute to dimerization,
strongly predicts that PGHS found in lower organisms exist as mono-
mers, rather than as the dimer observed in itsmammalian counterparts.
Whilemore quantitative analysis is needed, gelﬁltration in thepresence
of solubilizing detergents suggests that algal PGHS is tetrameric in solu-
tion [22]. Together, these observations might imply that the oligomers
formed by homologs from more primitive species rely on interfaces
unique to those observed in eukaryotic counterparts.
In eukaryotic proteins, the dimeric structure of PGHS has been
shown to be required for enzymatic function. Reversible disruption of
the PGHS dimer by mild denaturation yields a monomeric-but-folded
enzyme that lacks cyclooxygenase activity; activity is regained follow-
ing removal of denaturant [47]. More recent studies with mammalian
PGHS homodimers indicate that occupation of the active site of one
monomer in the dimer prevents binding of substrate or inhibitor to
the secondmonomer [12–16].While the oligomeric properties of a bac-
terial PGHS remain to be determined, detailed side-by-side biochemical
comparison of bacterial and eukaryotic PGHS would likely provide
meaningful insight into the relationship between oligomeric state and
catalysis, and the including the advantage of a “half of sites” reaction
mechanism observed in the oligomer state.
4.4. The catalytic domain
Gracilaria PGHS, Nostoc 10S-dioxygenase, and the Rhodobacter
ortholog align reasonably well over all residues to ovine PGHS-1, with
approximately 25-28% sequence identity and 44–46% positively corre-
lated amino acids (Table 1). Sequence alignments indicate that many
of the amino acid residues critical for catalytic activity in mammalian
PGHS are conserved in the bacterial and algal proteins. The quality of
the theoretical alignment and resulting structural models allows for
speculation on the signiﬁcance of conservation in the lipid binding
channel and peroxidase active site between the bacterial and algal pro-
teins and their mammalian counterpart.
4.4.1. The cyclooxygenase active site
Next, we compare the substrate binding sites of one algal and two
bacterial proteins to the same site in mammalian PGHS. The algal
PGHS prefers arachidonic acid as substrate, but can also oxidize other
C20 substrates with varying efﬁciencies. The substrate with the lowest
KM is 2-arachidonylglycerol, but this substrate is turned over at a rate
less than 20% of that seen with arachidonic acid [22]. In contrast, the
Nostoc 10S-dioxygenase bindsmost tightly to linolenic acid, and has vir-
tually no activity toward C20 substrates [21]. The selective pressure that
promotes diverse substrate speciﬁcity may be the availability of lipid
substrates. The algal PGHS prefers arachidonic acid as a substrate, and
arachidonic acid comprisesmore than 40% of the total fatty acid content
in some species of Gracilaria [93]. Lipid analyses of the cyanobacteria
Nostoc punctiforme indicate that arachidonic acid is not synthesized in
this organism [94], and that linoleic acid is the major fatty acid seen in
Nostoc cells in stationary phase [95]. Hence, despite sequence similari-
ties noted, it stands to reason that the native substrate for Nostoc
PGHS is different from its other counterparts. A comparison of the sub-
strate binding sites between these two enzymes should reveal amino
acid residues critical for adjusting the size of the lipid binding cavity
and the orientation of catalytic residues relative to the bound lipid.
In mammalian PGHS proteins, Arg120 plays a key role in substrate
and inhibitor binding, more so in PGHS-1 than PGHS-2. Mutational
studies demonstrate that the Arg120Gln mutant of PGHS-1 has similar
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approximately 20% of the cyclooxygenase activity of the wild type [96]
. The region containing Arg120 in ovine PGHS-1 is poorly conserved
through the bacterial and algal homologs (Fig. 4). In the mammalian
structures, Arg120 resides in the C-terminal half of α-helix D of the
membrane binding domain. In Rhodobacter, position 120 is occupied
by a histidine, while in Nostoc, Asn occupies this position in the
alignment. While it could be envisioned that the hydrogen bonding ca-
pacity could be retained by these residues, these substitutions do not ar-
rive in the same spatial position ideal for interaction with substrate in
our homology modeling (Fig. 2). Curiously, the Gracilaria ortholog has
a Pro in this position by sequence alignment but yet is most active to-
wards the substrate arachidonic acid; dihomo-γ-linolenic acid and
arachidonoylglycerol also show signiﬁcant activity [22]. Hence, the se-
quence requirements for substrate binding in these more primitive
orthologsmay be less reliant on the hydrogen bonding network provid-
ed in part by the triad of residues that includes Arg120 in eukaryotes.
Another determinant of substrate speciﬁcity in ovine PGHS-1 is Ile
523. In PGHS-2, this residue exists as Val and underlies the basis for iso-
form speciﬁcity of NSAIDs and different substrates. For example,
arachidonoylglycerol is an excellent substrate for human and murine
PGHS-2, but a very poor substrate for PGHS-1 [97], with the difference
in activity attributed to the identity at this position. Sequence align-
ments of the bacterial and algal proteins indicate a lack of consensus
at that position, favoring smaller hydrophobic residues (Fig. 4). This
might indicate variability in substrate speciﬁcity between species.
More broadly, of the 19 residues that line the cyclooxygenase active
site [57], eighteen are identical between human PGHS-1 and PGHS-2;
only position 523 differs (Ile523 in PGHS-1 and Val523 in PGHS-2)
[98]. Sequence alignments between the algal, bacterial, and ovine
PGHS-1 show similar homology, with the exception of Arg120, as afore-
mentioned. The region of amino acids corresponding to amino acids
348-355 and 521-525 also contribute signiﬁcant surface near andwith-
in the entrance of the hydrophobic substrate channel. The annulus of
large planar hydrophobic residues ﬂanking Tyr385 at the apex of the cy-
clooxygenase channel is also predicted to be preserved by sequence
alignment and homology modeling (Fig. 4). Also, Ser530, conserved in
the eukaryotic enzymes, is universally changed to Ala in the bacterial
enzymes and Thr in the algal enzyme. In eukaryotic PGHS-2, a
Ser530Ala mutation causes little change in substrate oxidation [60],
while Ser530Thr changes product production from PGG2 to 15R-HETE.
In PGHS-1, a Ser530Thr mutation inactivates the cyclooxygenase activ-
ity [99].
Thus, a simple comparison of active site amino acid residues is insuf-
ﬁcient to rationalize the observed differences in substrate speciﬁcity be-
tween the Gracilaria and Nostoc enzymes. The factors dictating binding
site architecture are certainly complex. For example, mutagenesis of
non-active site amino acid residues in Plexaura PGHS invert the stereo-
chemistry of dioxygen addition at C15 [100]. Experimental structures of
the various enzymes discussed will be required to completely under-
stand the structural basis for these substrate preferences.
4.4.2. The peroxidase active site
Bioinformatics andmodeling also suggest unique featureswithin the
heme binding site of the prokaryotic and algal PGHS homologs relative
to the ovine PGHS prototype. As mentioned earlier, His388 participates
in a hydrogen bonded network with Tyr504 and His386 via a well-
ordered bridgingwater molecule [41].While Rhodobacter andGracilaria
enzymes preserve Tyr at position 504, the Nostoc enzyme features Phe
at that position. Other bacterial orthologs similarly feature Phe or the
bulkier Trp at the same position. The mechanistic implications of this
substitution are two-fold. Firstly, the large hydrophobic substitution of
Phe or Trp at this position would be predicted to undermine the reduc-
tion potential conferred by the Tyr 504-mediated hydrogen bonding
network. Mutagenesis of this residue in ovine PGHS reduces but does
not abolish peroxidase activity. His386 is conserved throughouteukaryotic species, but this position is substitutedwith Arg in the bacte-
rial and algal enzymes, further arguing against the existence of the hy-
drogen bonding network as seen in available eukaryotic crystal
structures. These compositional differences might explain why theNos-
toc 10S-dioxygenase lacks the peroxidase activity observed in algal and
eukaryotic PGHS. The Rhodobacter ortholog has the samenetwork as the
algal PGHS, and knowing if this enzyme possesses peroxidase activity
would be of interest. The algal PGHS suggests that theHis386Arg substi-
tution is not critical for peroxidase activity. The cyclooxygenase and
peroxidase activities inmammalian PGHS are coupled [101]; this perox-
idase cycle is prerequisite for the formation of the tyrosyl radical needed
to catalyzes cyclooxygenase activity and subsequent self-inactivation.
Second, a second tyrosine radical species has been characterized that
originates at Tyr504 and is functionally important for both isoforms of
mammalian PGHS [102,103]. Hence, the Nostoc enzyme might have a
simpler radical structure than that observed in the eukaryotic homo-
logs, which could help to explain its dioxygenase activity relative to
the cyclooxygenase activity observed in the algal enzyme.
The distal face of the heme cofactor in ovine PGHS-1 is largely de-
ﬁned by two residues: the distal heme ligand His207 and Gln203
(Fig. 2). The distal histidine is conserved in the algal protein, but in the
bacterial homologs, the distal histidine is replaced by an aspartic acid
residue. In all cases, Gln203 is absolutely conserved. TheHis207Asp sub-
stitution seen in the bacterial proteins may also help to explain the lack
of peroxidase activity.
5. Summary and future directions
Bacterial and algal proteins have been highlighted that possess the
potential to perform both cyclooxygenase and peroxidase activities dis-
tinct from that observed in eukaryotic counterparts. Already, one such
bacterial protein has been demonstrated to act as a 10S-dioxygenase
but is surprisingly soluble (rather than membrane-associated). Howev-
er, while bioinformatics strongly indicates a common structural fold
that relates these many orthologs, only experimental structures of can
truly establish these structure-function relationships. Careful enzymol-
ogy, site-directed mutagenesis, biophysics, and x-ray crystallography
can help to further our understanding of the critical elements associated
with cyclooxygenase activity, peroxidase activity, oligomerization, and
membrane binding.
Not only do these orthologs provide a promising experimental sys-
tem to approach speciﬁc mechanistic and structural questions, but
also the opportunity to discern the biological roles that they play in
these lower organism. Further motivation in this area of study may
come from commercial providers of bioactive lipids. Access to recombi-
nant preparations of these diverse enzymes may facilitate large-scale
production of an array of bioactive lipids that are otherwise difﬁcult
and expensive to obtain frommammalian sources, or remain inaccessi-
ble to total chemical synthetic approaches.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamem.2014.09.011.
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